Systematic Reviews of Animal Experiments Demonstrate Poor Human Clinical and Toxicological Utility

The assumption that animal models are reasonably predictive of human outcomes provides the basis for their widespread use in toxicity testing and in biomedical research aimed at developing cures for human diseases. To investigate the validity of this assumption, the comprehensive Scopus biomedical bibliographic databases were searched for published systematic reviews of the human clinical or toxicological utility of animal experiments. In 20 reviews in which clinical utility was examined, the authors concluded that animal models were either significantly useful in contributing to the development of clinical interventions, or were substantially consistent with clinical outcomes, in only two cases, one of which was contentious. These included reviews of the clinical utility of experiments expected by ethics committees to lead to medical advances, of highly-cited experiments published in major journals, and of chimpanzee experiments — those involving the species considered most likely to be predictive of human outcomes. Seven additional reviews failed to clearly demonstrate utility in predicting human toxicological outcomes, such as carcinogenicity and teratogenicity. Consequently, animal data may not generally be assumed to be substantially useful for these purposes. Possible causes include interspecies differences, the distortion of outcomes arising from experimental environments and protocols, and the poor methodological quality of many animal experiments, which was evident in at least 11 reviews. No reviews existed in which the majority of animal experiments were of good methodological quality. Whilst the effects of some of these problems might be minimised with concerted effort (given their widespread prevalence), the limitations resulting from interspecies differences are likely to be technically and theoretically impossible to overcome. Non-animal models are generally required to pass formal scientific validation prior to their regulatory acceptance. In contrast, animal models are simply assumed to be predictive of human outcomes. These results demonstrate the invalidity of such assumptions. The consistent application of formal validation studies to all test models is clearly warranted, regardless of their animal, non-animal, historical, contemporary or possible future status. Likely benefits would include, the greater selection of models truly predictive of human outcomes, increased safety of people exposed to chemicals that have passed toxicity tests, increased efficiency during the development of human pharmaceuticals and other therapeutic interventions, and decreased wastage of animal, personnel and financial resources. The poor human clinical and toxicological utility of most animal models for which data exists, in conjunction with their generally substantial animal welfare and economic costs, justify a ban on animal models lacking scientific data clearly establishing their human predictivity or utility.

[1]  The Use of Animals in Medical Research , 1919, Nature.

[2]  L. Wallenstein,et al.  Neurotoxic reaction to chloromycetin. , 1952, Annals of internal medicine.

[3]  M. Avery,et al.  Species differences and the clinical trial of new drugs: A review , 1966, Clinical pharmacology and therapeutics.

[4]  W. C. Guenther A Sample Size Formula for the Hypergeometric , 1973 .

[5]  Barbara MacKinnon,et al.  "Animal Liberation: A New Ethics for Our Treatment of Animals," by Peter Singer , 1977 .

[6]  W. Scott,et al.  Comparative distribution and embryotoxicity of acetylsalicylic acid in pregnant rats and rhesus monkeys. , 1977, Toxicology and applied pharmacology.

[7]  Jack Green Asymptotic Sample Size for Given Confidence Interval Length , 1982 .

[8]  J. Ward,et al.  Pharmacology, Clinical Efficacy, and Adverse Effects of the Nonsteroidal Anti‐Inflammatory Agent Benoxaprofen , 1982, Pharmacotherapy.

[9]  G. Venning Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? , 1983, British medical journal.

[10]  S. Fukushima,et al.  Effects of butylated hydroxyanisole, butylated hydroxytoluene, and NaCl on gastric carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine in F344 rats. , 1984, Journal of the National Cancer Institute.

[11]  W. Scheld Therapy of streptococcal endocarditis: correlation of animal model and clinical studies. , 1987, The Journal of antimicrobial chemotherapy.

[12]  L. Bernstein,et al.  Interspecies extrapolation in carcinogenesis: prediction between rats and mice. , 1989, Environmental health perspectives.

[13]  R. Mead,et al.  The Design of Experiments , 1989 .

[14]  Shayne C. Gad,et al.  Model Selection in Toxicology: Principles and Practice , 1990 .

[15]  R. Mead,et al.  The Design of Experiments. , 1989 .

[16]  A. Detsky,et al.  Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.

[17]  W. Osswald [Ethics of animal research and application to humans]. , 1992, Acta medica portuguesa.

[18]  B. Scatton,et al.  Lack of neuroprotective effect of some σ ligands in a model of focal cerebral ischemia in the mouse , 1992, Brain Research.

[19]  S B Soumerai,et al.  Examining product risk in context. Market withdrawal of zomepirac as a case study. , 1993, JAMA.

[20]  Will all chemicals be carcinogenic to rodents when adequately evaluated? , 1993, Mutagenesis.

[21]  Hugh LaFollette,et al.  Animal experimentation: The legacy of Claude Bernard , 1994 .

[22]  D J Graham,et al.  Temafloxacin syndrome: review of 95 cases. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Huff,et al.  The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. , 1995, Environmental health perspectives.

[24]  Michael Balls,et al.  The Role of Prevalidation in the Development, Validation and Acceptance of Alternative Methods , 1995 .

[25]  M. Spedding,et al.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia , 1995, British journal of pharmacology.

[26]  Michael Balls,et al.  The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. , 1995, Alternatives to laboratory animals : ATLA.

[27]  Spielmann Horst,et al.  Practical Aspects of the Validation of Toxicity Test Procedures , 1995 .

[28]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[29]  W. Russell,et al.  The Three Rs: The Way Forward , 1995 .

[30]  J. Grotta,et al.  Treatment of experimental focal ischemia in rats with lubeluzole , 1996, Neuropharmacology.

[31]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[32]  Michael F. W. Festing Experimental design and husbandry , 1997, Experimental Gerontology.

[33]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[34]  K. Welch,et al.  Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1997, Archives of neurology.

[35]  B. Ames,et al.  What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. , 1998, Drug metabolism reviews.

[36]  P. Mulder,et al.  Different Effects of Calcium Antagonists in a Rat Model of Heart Failure , 1998, Cardiology.

[37]  Robert D. Combes,et al.  Reducing the Use of Laboratory Animals in Biomedical Research: Problems and Possible Solutions , 1998, Alternatives to laboratory animals : ATLA.

[38]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[39]  W. Pawlik [The significance of animals in biomedical research]. , 1998, Folia medica Cracoviensia.

[40]  G. Betton,et al.  The predictivity of the toxicity of pharmaceuticals in humans from animal data--an interim assessment. , 1998, Toxicology letters.

[41]  D. Villar,et al.  Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats. , 1998, Veterinary and human toxicology.

[42]  E. Schauber,et al.  Statistical power to detect main and interactive effects on the attributes of small-mammal populations , 1999 .

[43]  H. Voipio,et al.  Environmental enrichment may alter the number of rats needed to achieve statistical significance , 1999 .

[44]  Stroke Therapy Academic Industry Roundtable Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[45]  N. Goodman,et al.  Comparison of basic methods in clinical studies and in vitro tissue and cell culture studies reported in three anaesthesia journals. , 1999, British journal of anaesthesia.

[46]  J K Haseman,et al.  USING THE NTP DATABASE TO ASSESS THE VALUE OF RODENT CARCINOGENICITY STUDIES FOR DETERMINING HUMAN CANCER RISK , 2000, Drug metabolism reviews.

[47]  R. Ridley,et al.  Clomethiazole protects against hemineglect in a primate model of stroke , 2000, Brain Research Bulletin.

[48]  D. Rall LABORATORY ANIMAL TESTS AND HUMAN CANCER* , 2000, Drug metabolism reviews.

[49]  P. Fenner-Crisp,et al.  The Endocrine Disruptor Screening Program Developed by the U.S. Environmental Protection Agency , 2000 .

[50]  Therapeutic effect of tirilazad mesylate (U-74006F), mannitol, and their combination on experimental ischemia. , 2000, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[51]  M. Limburg,et al.  Nimodipine in Animal Model Experiments of Focal Cerebral Ischemia: A Systematic Review , 2001, Stroke.

[52]  V. Aiyagari,et al.  The Failure of Neuronal Protective Agents Versus the Success of Thrombolysis in the Treatment of Ischemic Stroke , 2001, Annals of the New York Academy of Sciences.

[53]  S Green,et al.  The TestSmart-HPV Program--development of an integrated approach for testing high production volume chemicals. , 2001, Regulatory toxicology and pharmacology : RTP.

[54]  I. Kwan,et al.  Is the normalisation of blood pressure in bleeding trauma patients harmful? , 2001, The Lancet.

[55]  F. M. Johnson Response to Tennant et al.: Attempts to replace the NTP rodent bioassay with transgenic alternatives are unlikely to succeed , 2001 .

[56]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[57]  E. A. Fishbein What price mice? , 2001, JAMA.

[58]  I. Kjellmer [Animal experiments are necessary. Coordinated control functions are difficult to study without the use of nature's most complex systems: mammals and human beings]. , 2002, Lakartidningen.

[59]  Irene Kwan,et al.  Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation , 2002, BMJ : British Medical Journal.

[60]  R. D. de Haan,et al.  Wound Healing in Cell Studies and Animal Model Experiments by Low Level Laser Therapy; Were Clinical Studies Justified? A Systematic Review , 2002, Lasers in Medical Science.

[61]  J. Huff Chemicals Studied and Evaluated in Long‐Term Carcinogenesis Bioassays by Both the Ramazzini Foundation and the National Toxicology Program , 2002, Annals of the New York Academy of Sciences.

[62]  F. Brom Science and society: different bioethical approaches towards animal experimentation. , 2002, ALTEX.

[63]  R. Zaleski,et al.  A tiered approach to assessing children's exposure: a review of methods and data. , 2002, Toxicology letters.

[64]  Douglas G Altman,et al.  Guidelines for the design and statistical analysis of experiments using laboratory animals. , 2002, ILAR journal.

[65]  A. Goldberg Use of animals in research: a science--society controversy? The American perspective: animal welfare issues. , 2002, ALTEX.

[66]  M. Stephens,et al.  Animal pain and distress in vaccine testing in the United States. , 2002, Developments in biologicals.

[67]  Piet G. van Schaick Zillesen,et al.  Sample Power and ExpDesign: Tools for Improving Design of Animal Experiments , 2003, Lab Animal.

[68]  S. Curry Why Have So Many Drugs with Stellar Results in Laboratory Stroke Models Failed in Clinical Trials? , 2003, Annals of the New York Academy of Sciences.

[69]  B. Rusche The 3Rs and animal welfare - conflict or the way forward? , 2003, ALTEX.

[70]  J. Mapstone,et al.  Fluid resuscitation strategies: a systematic review of animal trials. , 2003, The Journal of trauma.

[71]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[72]  Lester B Lave,et al.  Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. , 2003, Regulatory toxicology and pharmacology : RTP.

[73]  P. Austin,et al.  Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure. , 2003, Journal of cardiac failure.

[74]  Kennon Heard,et al.  Emergency medicine animal research: does use of randomization and blinding affect the results? , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[75]  M. Festing Good Experimental Design and Statistics Can save Animals, But how can it be Promoted? , 2004, Alternatives to laboratory animals : ATLA.

[76]  L. Carbone What animals want : expertise and advocacy in laboratory animal welfare policy , 2004 .

[77]  Henk van Wilgenburg,et al.  Experimental Design: Computer Simulation for Improving the Precision of an Experiment , 2004, Alternatives to laboratory animals : ATLA.

[78]  M. Festing Is the Use of Animals in Biomedical Research Still Necessary in 2002? Unfortunately, “Yes” , 2004, Alternatives to laboratory animals : ATLA.

[79]  P. Sandercock,et al.  Where is the evidence that animal research benefits humans? , 2004, BMJ : British Medical Journal.

[80]  Alan M Goldberg,et al.  TestSmart and Toxic Ignorance , 2004, Alternatives to laboratory animals : ATLA.

[81]  George Loizou,et al.  The Third FRAME Toxicity Committee: Working toward Greater Implementation of Alternatives in Toxicity Testing , 2004, Alternatives to laboratory animals : ATLA.

[82]  Chad B. Sandusky,et al.  Laboratory routines cause animal stress. , 2004, Contemporary topics in laboratory animal science.

[83]  William S Stokes,et al.  Selecting appropriate animal models and experimental designs for endocrine disruptor research and testing studies. , 2004, ILAR journal.

[84]  Grantley D Charles,et al.  In vitro models in endocrine disruptor screening. , 2004, ILAR journal.

[85]  M. Stephens,et al.  A Demographic Analysis of Primate Research in the United States , 2004, Alternatives to laboratory animals : ATLA.

[86]  Michael Balls,et al.  Are Animal Tests Inherently Valid? , 2004, Alternatives to laboratory animals : ATLA.

[87]  Terry S Peters,et al.  Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials? , 2005, Toxicologic pathology.

[88]  G. Donnan,et al.  Systematic review and meta‐analysis of the efficacy of melatonin in experimental stroke , 2005, Journal of pineal research.

[89]  Tom Baldwin,et al.  The ethics of research involving animals , 2005 .

[90]  R. Kolář,et al.  [Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects]. , 2005, ALTEX.

[91]  B. Rusche,et al.  [The use of transgenic animals in biomedical research in Germany. Part 1: Status Report 2001-2003]. , 2005, ALTEX.

[92]  P. Bath,et al.  A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. , 2005, Nitric oxide : biology and chemistry.

[93]  G. Donnan,et al.  Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[94]  W. Heuwieser,et al.  [Evidence based veterinary medicine]. , 2005, DTW. Deutsche tierarztliche Wochenschrift.

[95]  C. Hendriksen,et al.  Reduction Strategies in Animal Research: A Review of Scientific Approaches at the Intra-experimental, Supra-experimental and Extra-experimental Levels , 2005, Alternatives to laboratory animals : ATLA.

[96]  G. Glazko,et al.  Eighty percent of proteins are different between humans and chimpanzees. , 2005, Gene.

[97]  F. Pierre,et al.  How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. , 2005, European journal of cancer.

[98]  David Thomas,et al.  The Ethics of Research Involving Animals: A Review of the Nuffield Council on Bioethics Report from an Antivivisectionist Perspective , 2005, Alternatives to laboratory animals : ATLA.

[99]  Cjc Phillips Meta-analysis — a systematic and quantitative review of animal experiments to maximise the information derived , 2005, Animal Welfare.

[100]  Robert Combes,et al.  The Need for a Formal Invalidation Process for Animal and Non-animal Tests , 2005, Alternatives to laboratory animals : ATLA.

[101]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[102]  K. Schulz Assessing allocation concealment and blinding in randomised controlled trials: why bother? , 2000, Equine veterinary journal.

[103]  P. Bath,et al.  Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. , 2005, Free radical biology & medicine.

[104]  Cor J. Kalkman,et al.  Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia , 2005, Journal of Neurology.

[105]  Jarrod Bailey,et al.  Non-Human Primates in Medical Research and Drug Development: A Critical Review , 2005 .

[106]  A. Knight,et al.  The future of teratology research is in vitro , 2005 .

[107]  Kimmo Louekari,et al.  In Vitro Tests within the REACH Information Strategies , 2006, Alternatives to laboratory animals : ATLA.

[108]  M. Shirtliff,et al.  Experimental Osteomyelitis: What Have We Learned from Animal Studies about the Systemic Treatment of Osteomyelitis? , 2006, Journal of chemotherapy.

[109]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[110]  Chad B. Sandusky,et al.  Strategies to Reduce Animal Testing in US EPA's HPV Programme , 2006 .

[111]  Jonathan Balcombe,et al.  Animal Carcinogenicity Studies: 1. Poor Human Predictivity , 2006, Alternatives to laboratory animals : ATLA.

[112]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[113]  Robert Combes,et al.  TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals , 2006, Alternatives to laboratory animals : ATLA.

[114]  T Hartung,et al.  Toward an evidence-based toxicology , 2006, Human & experimental toxicology.

[115]  D. Redelmeier,et al.  Translation of research evidence from animals to humans. , 2006, JAMA.

[116]  J. Balcombe,et al.  Laboratory environments and rodents' behavioural needs: a review , 2006, Laboratory animals.

[117]  B. Rusche,et al.  [The use of transgenic animals in biomedical research in Germany. Part 2: Ethical evaluation of the use of transgenic animals in biomedical research and perspectives for the changeover in research to research animal-free methods]. , 2006, ALTEX.

[118]  Jonathan Balcombe,et al.  Animal Carcinogenicity Studies: 2. Obstacles to Extrapolation of Data to Humans , 2006, Alternatives to laboratory animals : ATLA.

[119]  L. Houdebine Transgenic animal models in biomedical research. , 2007, Methods in molecular biology.

[120]  D. Hackam,et al.  Translating animal research into clinical benefit , 2007, BMJ : British Medical Journal.

[121]  V. Beral,et al.  IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF CARelNOGENIC RISKS TO HUMANS' , 2008 .

[122]  A. Knight The Poor Contribution of Chimpanzee Experiments to Biomedical Progress , 2007, Journal of applied animal welfare science : JAAWS.

[123]  Ncbi National Center for Biotechnology Information , 2008 .